Security key
16385C203
Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (CMMB)
CUSIP: 16385C203
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Ordinary shares, no par value per share
- Shares outstanding
- 491,982,609
- Total 13F shares
- 351,560
- Share change
- -24,319
- Total reported value
- $551,949
- Price per share
- $1.57
- Number of holders
- 15
- Value change
- -$40,387
- Number of buys
- 8
- Number of sells
- 6
Report period
Q1 2026
Institutions
15
Top holders
10
CMMB full security history
Previous quarter: Q4 2025
Chemomab Therapeutics Ltd. SEC filings
Chemomab Therapeutics Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 16385C203
Recent filing periods:
Top shareholders of CMMB - Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Peter Thiel |
13D/G
|
— |
4.6%
|
22,631,200
|
$40,509,848 | $0 | 31 Dec 2025 | |
| MORGAN STANLEY |
13D/G
13F
|
Company |
3.2%
|
13,213,260
|
$15,327,382 | -$22,120,527 | 31 Jul 2025 | |
| OrbiMed Israel GP Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,241,274
|
$10,108,146 | — | 03 Jan 2023 | |
| George Adi Mor |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
485,379
mixed-class rows
|
$2,856,339 | — | 18 Mar 2026 | |
| OrbiMed Israel BioFund GP Limited Partnership |
13D/G
|
— |
4.8%
|
969,807
|
$1,328,636 | $0 | 18 Jun 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13D/G
|
— |
4.8%
|
900,428
|
$1,152,548 | $0 | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.02%
|
103,781
|
$171,239 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.02%
|
80,000
|
$132,000 | — | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.01%
|
51,793
|
$85,458 | — | 31 Dec 2025 | |
| KESTRA PRIVATE WEALTH SERVICES, LLC |
13F
|
Company |
0.01%
|
51,710
|
$85,322 | — | 31 Dec 2025 | |
| Neil Harris Cohen |
3/4/5
|
Director |
—
mixed-class rows
|
35,992
mixed-class rows
|
$50,268 | — | 18 Mar 2026 | |
| XTX Topco Ltd |
13F
|
Company |
0%
|
19,013
|
$31,371 | — | 31 Dec 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0%
|
17,856
|
$29,462 | — | 31 Dec 2025 | |
| Sigal Fatal |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
48,100
mixed-class rows
|
$26,185 | — | 18 Mar 2026 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0%
|
15,598
|
$25,737 | — | 31 Dec 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0%
|
10,933
|
$18,000 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
8,125
|
$13,406 | — | 31 Dec 2025 | |
| Dale R. Pfost |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
461,853
mixed-class rows
|
$12,567 | — | 14 Mar 2022 | |
| Donald Marvin. |
3/4/5
|
Executive VP, CFO & COO |
—
mixed-class rows
|
198,875
mixed-class rows
|
$10,054 | — | 16 Mar 2022 | |
| Joel Michael Maryles |
3/4/5
|
Director |
—
mixed-class rows
|
13,317
mixed-class rows
|
$7,203 | — | 24 May 2022 | |
| Nissim Darvish |
3/4/5
|
Director |
—
mixed-class rows
|
10,423
mixed-class rows
|
$6,032 | — | 18 Mar 2026 | |
| GAMMA Investing LLC |
13F
|
Company |
0%
|
2,514
|
$4,148 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
2,253
|
$3,717 | — | 31 Dec 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
26
|
$43 | — | 31 Dec 2025 | |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO |
13F
|
Company |
0%
|
2
|
$3 | — | 31 Dec 2025 | |
| Otto Erik |
13D/G
|
— |
6.3%
|
385,000
|
— | $0 | 10 Feb 2026 | |
| John Lawler |
3/4/5
|
Chief Development Officer |
—
class O/S missing
|
20,000
|
— | — | 18 Mar 2026 | |
| Jill M. Quigley |
3/4/5
|
Director |
—
class O/S missing
|
13,640
|
— | — | 18 Mar 2026 | |
| Alan Charles Moses |
3/4/5
|
Director |
—
class O/S missing
|
11,884
|
— | — | 18 Mar 2026 | |
| Claude Nicaise |
3/4/5
|
Director |
—
class O/S missing
|
11,884
|
— | — | 18 Mar 2026 |
Institutional Holders of Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (CMMB) as of Q1 2026
As of 31 Mar 2026,
Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (CMMB) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
351,560 shares.
The largest 10 holders included
ADAR1 Capital Management, LLC, CITADEL ADVISORS LLC, KESTRA PRIVATE WEALTH SERVICES, LLC, Ikarian Capital, LLC, XTX Topco Ltd, RHUMBLINE ADVISERS, SmartHarvest Portfolios, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, BNP PARIBAS FINANCIAL MARKETS, and Philadelphia Investment Partners, LLC.
This page lists
15
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
14
Q1 2026 holders
15
Holder diff
1
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.